Navigation Links
Echo Therapeutics Schedules Third Quarter 2013 Financial Results for Thursday, November 7, 2013
Date:11/1/2013

PHILADELPHIA, Nov. 1, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it will release third quarter 2013 financial results on Thursday, November 7, 2013.  Management will hold a conference call to review the company's third quarter 2013 performance starting at 9:00 a.m. ET on the same day. 

The dial-in number is (877) 300-8521 and reference Echo Therapeutics 3rd Quarter 2013 Earnings Call.  The archived audiocast will be available for fourteen days following the call by visiting the Events section of Echo's website at www.echotx.com.

About Echo Therapeutics

Echo Therapeutics is developing the Symphony CGM System as a non-invasive, wireless, continuous glucose monitoring system for use initially in the critical care setting. Significant opportunity also exists for Symphony to be used in the hospital beyond the critical care setting, as well as in patients with diabetes in the outpatient setting. Echo is also developing its needle-free skin preparation component of Symphony, the Prelude® SkinPrep System, as a platform technology to enhance delivery of topical pharmaceuticals.

For More Information:
Christine H. Olimpio   
Director, Investor Relations and Corporate Communications
(215) 717-4104 
colimpio@echotx.com 

Connect With Us:
- Visit our website at www.echotx.com 
- Follow us on Twitter at www.twitter.com/echotx 
- Join us on Facebook at www.facebook.com/echotx 


'/>"/>
SOURCE Echo Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. G1 Therapeutics to Present at Southeast BIO Investor & Partnering Forum
2. Cell Therapeutics Reports Third Quarter 2013 Financial Results
3. Sorrento Therapeutics Announces Closing of Public Offering of Common Stock
4. Abide Therapeutics Appoints Dr. Gary ONeill as Vice President of Biology
5. Boston Scientific Announces Schedule Of Major Presentations At Transcatheter Cardiovascular Therapeutics 2013
6. Juventas Therapeutics completes enrollment of Phase II STOP-HF study of JVS-100 in patients with symptomatic heart failure
7. Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ
8. ISSYS Inc. will showcase its Titan Wireless Implantable Hemodynamic Monitor and its clinical study summary at the 25th Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference (Booth 1638) in San Francisco (October 29 to 31, 2013)
9. Aratana Therapeutics Adds to Commercial Leadership Team
10. Mirati Therapeutics Prices Public Offering Of Common Stock
11. Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 NeuroVive ... ("NeuroVive") today announced positive preclinical results demonstrating ... compound for non-alcoholic steatohepatitis (NASH), in an ... NV556 has previously shown similar ... model. Today, NeuroVive,s scientists present novel data ...
(Date:4/19/2017)... April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) ... & Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... , Chief Executive Officer of the Company is scheduled to present ... Richard Bear and the Chairman of the Board, Tony ... ...
(Date:4/19/2017)... April 19, 2017 The Mobile X-Ray product segment ... healthy CAGR during the forecast period Mobile X-Ray ... global digital mobile X-Ray devices market, which is estimated to ... expanding at a CAGR of 7% over the forecast period. ... of more than US$ 100 Mn in 2017 over 2016. ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... , ... An April 24th article on Yahoo! Beauty discusses the case of Jessica ... a weight loss surgery. The woman, declaring “I will not hate my body anymore!” posted ... dramatic weight loss. Dr. Feiz & Associates notes that, while it often refers its patients ...
(Date:4/28/2017)... ... April 28, 2017 , ... Accreditation Commission for ... Care Association of America (HCAOA). This agreement allows HCAOA members to receive special ... as discounts on Accreditation University (AU) educational resources that help prepare HCAOA members ...
(Date:4/28/2017)... ... April 28, 2017 , ... Somnoware, ... of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to create and edit their ... reporting process and provides a familiar interface that does not require additional training ...
(Date:4/28/2017)... ... 2017 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced ... its outlook as “stable.” At the same time, the ratings agency cautioned that the ... dip below “capital adequacy” thresholds required for its strong rating. , “Horizon is committed ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. ... GlycoMark test throughout the Northeast U.S. , GlycoMark is the only clinically ... GlycoMark test provides a clinically proven one- to two-week measure of hyperglycemic excursions, ...
Breaking Medicine News(10 mins):